公开(公告)号：US20180221382A1

公开(公告)日：2018-08-09

申请号：US15506421

申请日：2015-08-21

Applicant: STC UNM

Inventor： Ellen Janine Beswick

IPC: A61K31/553 ,  A61K31/165 ,  A61K31/551 ,  A61K31/4709 ,  A61K31/496 ,  A61K38/00 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K31/553 ,  A61K31/165 ,  A61K31/167 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/551 ,  A61K38/005 ,  A61K45/06 ,  A61K2300/00 ,  A61P35/00

Abstract: The present invention relates to the discovery that MK2 is highly expressed in cancer tissue and the inhibition of MK2 using an MK2 inhibitor represents a viable approach to the treatment of cancer, including drug resistant cancers, metastatic cancers and recurrent cancers. MK2 inhibitors as described herein may be used alone or in combination with an at least one additional anti-cancer agent for the treatment of cancer.